Breast Cancer Metastatic Clinical Trial
Official title:
A Randomized, Parallel, Open-label, Positive Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in HER2-negative Locally Advanced or Metastatic Breast Cancer Patients With Germline BRCA Mutations
This research study is evaluating the efficacy and safety of TSL-1502 capsules in patients with breast cancer, will be included HER2-negative locally advanced or metastatic breast cancer patients with germline BRCA mutations.
Status | Not yet recruiting |
Enrollment | 125 |
Est. completion date | June 30, 2026 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - 1) Agree to follow the clinical trial protocol, volunteer, and sign the informed consent form (ICF). 2) Women aged = 18 years and = 75 years at the date of signing the ICF. 3) HER2-locally advanced breast cancer diagnosed by histopathology and/or cytology (Unable to receive radical therapy) or metastatic breast cancer, and previous chemotherapeutic line of cytotoxicity for locally advanced or metastatic breast cancer was = 1 (for triple-negative breast cancer only) and = 3. 4) Prior platinum therapy is allowed, but the best response to platinum therapy is required to be CR, PR, or persistent = 12 weeks SD. If given as neoadjuvant/adjuvant therapy, the time from the last dose of platinum to relapse is = 6 months. 5) Hormone receptor-positive patients need to have received at least first-line of endocrine therapy for locally advanced or metastatic breast cancer but failed, or unsuitable for endocrine therapy in the judgment of the investigator. 6) In neoadjuvant, adjuvant and/or metastatic stages, the patients who have received antitumor therapy with Taxane ± Anthracycline. 7) Failure of front-line therapy (disease progression or toxicity intolerance), and the investigator judged that it was suitable to receive the systemic monotherapy (including capecitabine tablets, vinorelbine tartrate injection, eribulin mesylate injection). 8) Tested or reviewed by a third-party central laboratory to determine whether there is harmful or suspected harmful gBBRCAm in the blood. 9) At least one measurable (non-lymph node longest diameter = 10 mm, lymph nodes with a minimum diameter of = 15 mm, according to RECIST version 1.1 criteria) of target lesions. Note: Previously irradiated lesions cannot be used as targets lesions unless there is significant progression of the lesion. 10) The physical condition score is 0-1 according to the scale of The Eastern Cooperative Oncology Group (ECOG). 11) Expected survival = 12 weeks. 12) Meet the following criteria (The use of any blood components and cell growth factors is not permitted within 2 weeks prior to initial administration): Bone marrow function: absolute neutrophil count (ANC) = 1.5 × 109/L (1500/mm3); platelets = 100 × 109/L (1 × 105/mm3); Hemoglobin = 90 g/L; Liver function: serum bilirubin = 1.5 × upper limit of normal (ULN), but except for Gilbert's syndrome patients (persistent or recurrent hyperbilirubinemia, unbound bilirubin elevation is present in the absence of evidence of hemolysis or liver pathology); patients without liver metastasis, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5×ULN; ALT and AST = 5×ULN for patients with liver metastasis; Renal function: serum creatinine = 1.5 × ULN, or creatinine clearance (Ccr) = 50 mL/min (Calculated according to the Cockcroft-Gault formula); Cockcroft-Gault formula: female Ccr (mL/min) = 0.85 × weight (kg) × (140-age)/ [72 × creatinine (mg/dL)] Coagulation function: international normalized ratio (INR) = 1.5 × ULN, activated partial thromboplastin time (APTT) = 1.5 × ULN. 13) Women of childbearing age are willing to take effective contraception from signing the ICF to 6 months after the last administration of the investigational drug. Women of childbearing age must have a negative blood pregnancy test result 7 days before the first dose. Exclusion Criteria: - 1) Pregnant or lactating women. 2) Active inflammatory breast cancer. 3) Previous treatment with other PARP inhibitor drugs, including but not limited to TSL-1502, Olaparib, Talazoparil, Fluzoparil, Nilaparib, Rucaparib, Veliparib, etc. 4) Known to be allergic to TSL-1502 or any excipient of TSL-1502 capsules. 5) Known to have active brain metastases (defined as meeting any of the following: stable neurological imaging < 4 weeks; symptoms related to brain metastasis; steroid therapy required; leptomeningeal disease); patients must have completed any prior treatment for brain metastases = 4 weeks prior to the first dose. 6) Patients with previous or current another malignancy. 7) Have other serious or uncontrollable clinical diseases or past medical history, surgical history, including but not limited to hepatic/renal dysfunction, respiratory disorders, endocrine disorders, metabolic disorders, neuropathy, or mental disorders, organ transplantation, etc. 8) Gastrointestinal or digestive system diseases that may affect the absorption of investigational products as judged by the investigator or past medical history, such as intractable hiccups, nausea, vomiting, chronic gastrointestinal disease (e.g. Ron's disease, ulcerative colitis, active gastric ulcer, etc.), dysphagia, etc. 9) Have serious cardiovascular system disease or past medical history (meet any of the following conditions); Definite cardiovascular abnormality within 6 months prior to first dose (e.g., myocardial infarction, cardiac arrhythmia, angina pectoris, angioplasty, vascular stent implantation, coronary artery bypass surgery, congestive heart failure, etc.); Baseline electrocardiogram QT or Fridericia-corrected QT interval (QTcF) prolongation [QTcF = QT/(RR 0.33), QTcF > 480 ms]; Left ventricular ejection fraction < 50% by cardiac ultrasound; Uncontrolled hypertension (Patients with blood pressure =150/100 mmHg after lifestyle improvement and medication) 10) Participated in clinical trials of other drugs or medical devices within 4 weeks prior to initial administration (note: except for those who did not use investigational drugs or medical devices). 11) Patients who underwent major surgery or significant traumatic injury within 4 weeks prior to initial administration, or who planned to undergo major surgery in the trial period. 12) Chemotherapy, radiotherapy, non-hormone targeted therapy, endocrine therapy, Anti-neoplastic immunotherapy [physiologic replacement doses of corticosteroids permitted (prednisone or equivalent < 15 mg/day)], Chinese medicine therapy with a clear indication for the treatment of breast cancer, or other anti-tumor therapy were received within 4 weeks prior to initial administration. 13) AEs related to previous surgery and previous anti-tumor therapy (CTCAE version 5.0) did not recover to = 1 grade (alopecia, pigmentation, platinum-induced neurotoxicity grade 2 and lower, except for clinically significant or asymptomatic laboratory abnormalities). 14) Patients who had received a CYP2D6 liver enzyme inhibitors or inducers within 2 weeks prior to initial dosing, or who cannot discontinue the use of CYP2D6 liver enzyme inhibitors or inducers during the trial. 15) Patients who test positive for treponema pallidum antibody, human immunodeficiency virus (HIV) antibody, hepatitis C virus (HCV) RNA, or active hepatitis B patients [defined as hepatitis B virus (HBV) DNA = ULN]. 16) The investigator considered that patients have other conditions that might affect compliance or are not suitable for participating in this trial. |
Country | Name | City | State |
---|---|---|---|
China | Cancer Hospital, Chinese Academy of Medical Sciences | Beijing |
Lead Sponsor | Collaborator |
---|---|
Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Cmax | Plasma concentrations for TSL-1502 and TSL-1502M will be analyzed to determine the maximum observed concentration | Cycle1(Day1?Day8?Day14 and Day21) | |
Other | Cmin | Plasma concentrations for TSL-1502 and TSL-1502M will be analyzed to determine the minimum observed concentration | Cycle1(Day1?Day8?Day14 and Day21) | |
Other | AUC0-t | Plasma concentrations for TSL-1502 and TSL-1502M will be analyzed to determine the area under the curve (AUC). | Cycle1(Day1?Day8?Day14 and Day21) | |
Primary | Objective response rate(ORR) | Defined as the proportion of patients with complete response (CR) and partial response (PR). Solid tumors evaluation criteria (RECIST) version 1.1 is used for anti-tumor efficacy evaluation. For patients with PR or CR at the first evaluation, response confirmation should be performed at least 4 weeks later | Radiological scans performed at baseline then every 6 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 40 months | |
Secondary | Disease Control Rate(DCR) | DCR is defined as the proportion of patients with CR, PR and stable disease (SD). | Radiological scans performed at baseline then every 6 weeks there after until disease progression or death due to any cause.Assessed up to a maximum of 40 months | |
Secondary | Duration of Response(DOR) | DOR is defined as the time from the first assessment of CR or PR to disease progression or death due to any cause. | Radiological scans performed at baseline then every 6 weeks there after until disease progression or death due to any cause.Assessed up to a maximum of 40 months | |
Secondary | Progress Free Survival(PFS) | PFS is defined as the time from randomization to the first disease progression or death due to any cause, whichever occurs first. 12 Months PFS Rate is defined as the percentage of subjects without disease progression or death from any cause 12 months after the beginning of randomization or the probability estimated by Kaplan-Meier method. | Radiological scans performed at baseline then every 6 weeks there after until disease progression or death due to any cause.Assessed up to a maximum of 40 months | |
Secondary | Overall Survival(OS) | OS is defined as the time from randomization to death due to any cause. | Radiological scans performed at baseline then every 6 weeks there after until disease progression or death due to any cause.Assessed up to a maximum of 40 months | |
Secondary | 12 Months PFS Rate | 12 Months PFS Rate is defined as the percentage of subjects without disease progression or death from any cause 12 months after the beginning of randomization or the probability estimated by Kaplan-Meier method. | Radiological scans performed at baseline then every 6 weeks there after until disease progression or death due to any cause.Assessed up to a maximum of 40 months | |
Secondary | Safety endpoints | all AEs and SAEs by CTCAE v5.0 | From screening until final visit.Assessed up to a maximum of 40 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04123704 -
Sitravatinib in Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04509596 -
DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04122469 -
The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease
|
N/A | |
Completed |
NCT03045653 -
Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer
|
Phase 2 | |
Terminated |
NCT03322215 -
HR+/HER2- Advanced Breast Cancer and Endocrine Resistance
|
Phase 2 | |
Active, not recruiting |
NCT04059484 -
Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer
|
Phase 2 | |
Recruiting |
NCT04368442 -
Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation
|
||
Terminated |
NCT03709082 -
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT03642990 -
NR in Chemo-induced Peripheral Neuropathy
|
Phase 2 | |
Terminated |
NCT01876251 -
A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04483505 -
Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.
|
Phase 1 | |
Recruiting |
NCT03086785 -
Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer
|
Phase 2 | |
Terminated |
NCT04197999 -
A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer
|
Phase 1 | |
Not yet recruiting |
NCT03638765 -
Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer
|
Phase 1 | |
Recruiting |
NCT06100874 -
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After progrEssion on ENhertu (SATEEN)
|
Phase 2 | |
Completed |
NCT05609903 -
Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer
|
||
Active, not recruiting |
NCT04597580 -
Personalised Disease Monitoring in Metastatic Breast Cancer
|
||
Completed |
NCT05301530 -
Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.
|
Phase 1 | |
Active, not recruiting |
NCT03328884 -
Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients
|
Phase 2 | |
Recruiting |
NCT05837533 -
Multicenter Study to Evaluate a Systematized Communication Model for Breast Cancer Patients
|
N/A |